Citadel Advisors
GH icon

Citadel Advisors’s Guardant Health GH Stock Holding History

Citadel Advisors’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.8M Sell
139,000
-38,600
-22% -$3.88M ﹤0.01% 2891
2025
Q4 		$18.1M Sell
177,600
-12,800
-7% -$1.15M ﹤0.01% 2481
2025
Q3 		$11.9M Buy
190,400
+61,900
+48% +$3.37M ﹤0.01% 3004
2025
Q2 		$6.69M Sell
128,500
-71,600
-36% -$3.2M ﹤0.01% 3626
2025
Q1 		$8.52M Buy
200,100
+64,300
+47% +$2.77M ﹤0.01% 3070
2024
Q4 		$4.15M Buy
135,800
+45,000
+50% +$1.27M ﹤0.01% 4272
2024
Q3 		$2.08M Buy
90,800
+24,600
+37% +$696K ﹤0.01% 5452
2024
Q2 		$1.91M Sell
66,200
-814,600
-92% -$19M ﹤0.01% 5408
2024
Q1 		$18.2M Buy
880,800
+810,100
+1,146% +$17.4M ﹤0.01% 2177
2023
Q4 		$1.91M Buy
70,700
+18,600
+36% +$488K ﹤0.01% 5442
2023
Q3 		$1.54M Buy
52,100
+6,600
+15% +$232K ﹤0.01% 5701
2023
Q2 		$1.63M Sell
45,500
-36,600
-45% -$1.05M ﹤0.01% 5533
2023
Q1 		$1.92M Sell
82,100
-126,200
-61% -$3.6M ﹤0.01% 5461
2022
Q4 		$5.67M Sell
208,300
-228,000
-52% -$10.4M ﹤0.01% 3647
2022
Q3 		$23.5M Buy
436,300
+115,400
+36% +$5.92M 0.01% 1720
2022
Q2 		$12.9M Buy
320,900
+66,100
+26% +$3.28M ﹤0.01% 2357
2022
Q1 		$16.9M Buy
254,800
+50,200
+25% +$3.44M ﹤0.01% 2197
2021
Q4 		$20.5M Buy
204,600
+52,200
+34% +$5.4M ﹤0.01% 1988
2021
Q3 		$19.1M Buy
152,400
+56,800
+59% +$6.75M ﹤0.01% 2070
2021
Q2 		$11.9M Sell
95,600
-12,100
-11% -$1.63M ﹤0.01% 2818
2021
Q1 		$16.4M Buy
107,700
+21,800
+25% +$3.29M ﹤0.01% 2225
2020
Q4 		$11.1M Sell
85,900
-68,100
-44% -$7.84M ﹤0.01% 2505
2020
Q3 		$17.2M Buy
154,000
+92,800
+152% +$8.49M ﹤0.01% 1697
2020
Q2 		$4.96M Sell
61,200
-11,000
-15% -$886K ﹤0.01% 3091
2020
Q1 		$5.03M Sell
72,200
-9,600
-12% -$737K ﹤0.01% 2697
2019
Q4 		$6.39M Sell
81,800
-12,900
-14% -$930K ﹤0.01% 2778
2019
Q3 		$6.04M Buy
94,700
+22,600
+31% +$1.99M ﹤0.01% 2848
2019
Q2 		$6.22M Buy
72,100
+49,000
+212% +$3.74M ﹤0.01% 2779
2019
Q1 		$1.77M Buy
+23,100
New +$1.28M ﹤0.01% 4666

Other funds holding GH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's GH Position: Q1 2026 in Review

Citadel Advisors increased its Guardant Health (GH) stake by 37% in Q1 2026, buying an estimated $21.2M and bringing the position to 775,941 shares worth $71.7M. The position accounts for 0.01% of the portfolio, ranked #1059.

Citadel Advisors first reported a position in GH in Q1 2019 and has held it in 28 quarters since. The position peaked at $153M in Q1 2025. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.

  • Citadel Advisors held 775,941 shares of Guardant Health worth $71.7M as of Q1 2026.
  • Citadel Advisors bought 211,599 Guardant Health shares in Q1 2026, an estimated $21.2M.
  • Guardant Health made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1059 holding.
  • Citadel Advisors first reported a position in Guardant Health in Q1 2019 and has held it in 28 quarters since.
  • Citadel Advisors's Guardant Health position peaked at $153M in Q1 2025.
  • 481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.